^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    2d
    Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China. (PubMed, EClinicalMedicine)
    Patients with resectable stage II-IIIB EGFR (AJCC 8th edition) mutant NSCLC were enroled and received neoadjuvant sintilimab (200 mg) plus carboplatin (area under the curve 5) and nab-paclitaxel (260 mg/m2) for 3 cycles. Patients in stage II cohort received adjuvant osimertinib for up to 2 years while observation for stage I cohort...provided PD-1 regimen (sintilimab), participant compensation and insurance. This work was supported by National Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China National High-Level Talents Special Support Program, National Natural Science Foundation of China Major Joint Project on Key scientific issues of lung Cancer, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer, Integrated Project of Major Research Plan of National Natural Science Foundation of China, National Health Commission Medical and Health Technology Development Research Centre Project.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    RB1 (RB Transcriptional Corepressor 1) • RBM10 (RNA Binding Motif Protein 10)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • Tozaride (Rhenium (Re) 188 P2045)
    5d
    A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (clinicaltrials.gov)
    P1, N=142, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=72 --> 142
    Trial completion • Enrollment change
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • axitinib
    5d
    Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=12, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    5d
    HCHTOG2603: A Multicenter, Open-Label, Randomized Controlled Phase III Clinical Trial Comparing Surgery Versus Radical Chemoradiotherapy (Organ Preservation) in Patients With Thoracic Esophageal Squamous Cell Carcinoma Achieving cCR or cPR Following Neoadjuvant Immunochemotherapy (clinicaltrials.gov)
    P3, N=1044, Not yet recruiting, Henan Cancer Hospital
    New P3 trial
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    6d
    Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (clinicaltrials.gov)
    P1, N=60, Recruiting, University of Rochester | N=28 --> 60
    Enrollment change
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • pemetrexed
    6d
    Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    albumin-bound paclitaxel
    6d
    Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Oct 2031 --> Apr 2032 | Initiation date: Apr 2026 --> Nov 2026 | Trial primary completion date: Jan 2031 --> Jan 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Idafang (ivonescimab)
    6d
    Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    6d
    CATPCC-01: Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Apr 2029
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    7d
    A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (clinicaltrials.gov)
    P2/3, N=470, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • navlimetostat (BMS-986504)
    7d
    Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2029 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • gemcitabine • capecitabine • albumin-bound paclitaxel • irinotecan
    7d
    HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients (clinicaltrials.gov)
    P2, N=133, Recruiting, Zhejiang University | N=32 --> 133
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642